3-(4-氯苯基)丙酸 | 2019-34-3

• 物质功能分类: 化学试剂 - 有机试剂 - 芳香酸
• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 中文名称: 3-(4-氯苯基)丙酸
• 中文别名: 对氯苯丙酸
• 英文名称: 3-(4-chlorophenyl)propanoic acid
• 英文别名: 3-(4-chlorophenyl)propionic acid
• CAS: 2019-34-3
• 化学式: C₉H₉ClO₂
• mdl: MFCD00016555
• 分子量: 184.622
• InChiKey: BBSLOKZINKEUCR-UHFFFAOYSA-N

物化性质

• 熔点：
  127-131 °C (lit.)
• 沸点：
  263.86°C (rough estimate)
• 密度：
  1.1989 (rough estimate)
• 稳定性/保质期：
  如果按照规格正确使用和储存，则不会分解，不存在已知的危险反应，应避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R22,R41
• WGK Germany：
  2
• 海关编码：
  2916399090
• 危险品运输编号：
  NONH for all modes of transport
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  请将贮藏器密封保存，在阴凉、干燥处存放，并确保工作环境具有良好的通风或排气设施。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
3-(4-Chlorophenyl)propanoic acid
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H318: Causes serious eye damage
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-(4-Chlorophenyl)propanoic acid
CAS number: 2019-34-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
This product should be handled only by, or under the close supervision of, those properly qualified
Handling:
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H9ClO2
Molecular weight: 184.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

化学性质
无色结晶。熔点为126℃（范围在121-122.5℃之间）。能溶于四氯化碳。

用途
作为除草剂麦敌散的中间体。

生产方法
由对氯苯丙烯酸电解还原制得。还原过程在装有渗透性隔膜容器的双层电解槽中进行。外槽用水银覆盖，槽底作阴极，阳极为螺旋形铅片悬于内槽中央。阴极电解液中有电动搅拌器，开始时分别向内外两槽加入7-8%的硫酸钠溶液，随后以0.5-0.7mol/L的比例将对氯肉桂酸悬浮在内槽电解液中，并启动搅拌器。在阴极电解液中按每摩尔对氯肉桂酸加入0.6-0.8mol氢氧化钠的比例添加碱溶液。接通直流电源进行电解还原，实验中的电压为10-20V，电流约为0.8-3A。还原1摩尔的对氯肉桂酸大约需要60-65A·h电量。

还原完毕后，使用倾泻法或虹吸分离阴极电解液和水银，滤除少量不溶物，并用过量硫酸（1：1）酸化处理，再经抽滤、洗涤及干燥后得到白色粉末固体，产率约为80%。通过四氯化碳提纯可获得成品。

反应信息

• 作为反应物：
  描述：

  3-(4-氯苯基)丙酸 在 Zn(2,2,6,6-tetramethylpiperidine)_2*2LiCl 、 bis(η3-allyl-μ-chloropalladium(II)) 、 乙酸烯丙酯 作用下， 以 四氢呋喃 为溶剂， 反应 4.5h， 以66%的产率得到对氯肉桂酸
  参考文献：
  名称：

  烯丙基钯催化羧酸的α，β-脱氢

  摘要：

  据报道，通过烯丙基钯催化，烯醇盐可实现高度实用且分步经济的羧酸α，β-脱氢。使用锌（TMP）时产生二价阴离子经历平滑脱氢2 ⋅2的LiCl为在过量的ZnCl的存在下与碱2，从而避免了这些基材的典型脱羧途径。直接获得2-烯酸可以通过多种方法衍生化。

  DOI：

  10.1002/anie.201706893
• 作为产物：
  描述：

  对氯肉桂酸 在 1,2,3,4-四氢萘 、 钯 作用下， 反应 1.5h， 生成 3-(4-氯苯基)丙酸
  参考文献：
  名称：

  Synthesized Drug from Medicinal Plant phytochemicals Effectively Targets ECM1 Gene Mutations in Ulcerative Colitis

  摘要：

  溃疡性结肠炎（UC）是一种主要影响结肠粘膜的炎症性肠道疾病。根据其出现的方式，它可以影响整个结肠甚至远端直肠。UC可以影响男女各年龄段的人群，但大多数患者通常在15至30岁之间出现。细胞外基质蛋白-1（ECM1）基因是一个重要的候选基因，ECM1单核苷酸多态性的突变可能导致患者组织损伤，从而加剧由金属蛋白酶9引起的组织损伤，导致UC。在这项分析中，从中国齐鲁医院中医科学委员会获得了化合物合成的批准。选择了用作UC治疗的几种衍生物来构建药效团模型，采用基于配体的药效团建模方法进行虚拟筛选，以识别合适的药物化合物。然后在体外合成了选定的化合物，并使用分子对接技术进行验证。合成的化合物符合其他药物相似性法则的非毒性存在的所有特征。对接复合物中发现的特定交互氨基酸包括精氨酸（ARG）：47，赖氨酸（LYS）：54，苯丙氨酸（PHE）：141，天冬氨酸（ASN）：51，丝氨酸（SER）：219，组氨酸（HIS）：144，PHE：214，缬氨酸（VAL）：220，酪氨酸（TYR）：145和TYR：284。合成化合物与ECM1基因中突变的TYR：284的相互作用证实了药物分子作为溃疡性结肠炎治疗药物的可行性和安全性。未来可以在实验室中探索其有效性，并将这种合成化合物用作临床研究中针对ECM1基因中TYR：284突变的药物靶点。

  DOI：

  10.2174/1570180818666210804130050

文献信息

• [EN] 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY<br/>[FR] 2,4-DIAMINOQUINAZOLINES UTILES POUR LE TRAITEMENT D'UNE ATROPHIE MUSCULAIRE SPINALE
  申请人：DECODE CHEMISTRY INC

  公开号：WO2005123724A1

  公开（公告）日：2005-12-29

  2,4-Diaminoquinazolines of formulae I-IV and VI (I, II, III, IV and VI) are useful for treating spinal muscular atrophy (SMA).

  2,4-二氨基喹唑啉的化学式I-IV和VI（I，II，III，IV和VI）可用于治疗脊髓性肌萎缩症（SMA）。
• [EN] SUBSTITUTED BENZAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE BENZAMIDE SUBSTITUÉS
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011076678A1

  公开（公告）日：2011-06-30

  The invention relates to compounds of formula I wherein R is hydrogen or lower alkyl; R1 is -(CH2)n-(O)o-heterocycloalkyl or -C(O)-heterocycloalkyl, wherein the heterocycloalkyl group is optionally substituted by lower alkyl, hydroxy, halogen or by -(CH2)p-aryl; n is 0, 1 or 2; o is 0 or 1; p is 0, 1 or 2; R2 is CF3, cycloalkyl, optionally substituted by lower alkoxy or halogen, or is indan-2-yl, or is heterocycloalkyl, optionally substituted by heteroaryl, or is aryl or heteroaryl, wherein the aromatic rings are optionally substituted by one or two substituents, selected from lower alkyl, halogen, heteroaryl, hydroxy, CF3, OCF3, OCH2CF3, OCH2-cycloalkyl, OCH2C(CH2OH)(CH2C1)(CH3), S-lower alkyl, lower alkoxy, CH2-lower alkoxy, lower alkinyl or cyano, or by-C(O)-phenyl, -O-phenyl, -O- CH2-phenyl, phenyl or -CH2-phenyl, and wherein the phenyl rings may optionally be substituted by halogen, -C(O)-lower alkyl, -C(O)OH or -C(O)O-lower alkyl, or the aromatic rings are optionally substituted by heterocycloalkyl, OCH2-oxetan-3-yl or O-tetrahydropyran-4-yl, optionally substituted by lower alkyl; X is a bond, -NR'-, -CH2NH-, -CHR''-, -(CHR'')q-O-, -O-(CHR'')q- or -(CH2)2-; Y is a bond or -CH2- R' is hydrogen or lower alkyl, R'' is hydrogen, lower alkyl, CF3, lower alkoxy, q is 0, 1, 2 or 3; or to a pharmaceutically suitable acid addition salt thereof. It has now been found that the compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinsons disease, neurodegenerative disorders such as Alzheimers disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  该发明涉及以下式I的化合物，其中R是氢或较低的烷基；R1是-(CH2)n-(O)o-杂环烷基或-C(O)-杂环烷基，其中杂环烷基基团可选择地被较低的烷基，羟基，卤素或-(CH2)p-芳基取代；n为0、1或2；o为0或1；p为0、1或2；R2为CF3，环烷基，可选择地被较低的烷氧基或卤素取代，或为茚-2-基，或为杂环烷基，可选择地被杂芳基取代，或为芳基或杂芳基，其中芳香环可选择地被来自较低的烷基，卤素，杂芳基，羟基，CF3，OCF3，OCH2CF3，OCH2-环烷基，OCH2C(CH2OH)(CH2C1)(CH3)，S-较低的烷基，较低的烷氧基，CH2-较低的烷氧基，较低的炔基或氰基，或-C(O)-苯基，-O-苯基，-O-CH2-苯基，苯基或-CH2-苯基选择的一个或两个取代基取代，其中苯环可选择地被卤素，-C(O)-较低的烷基，-C(O)OH或-C(O)O-较低的烷基取代，或芳香环可选择地被杂环烷基，OCH2-氧杂环戊烷-3-基或O-四氢吡喃-4-基，可选择地被较低的烷基取代；X为键，-NR'-，-CH2NH-，-CHR''-，-(CHR'')q-O-，-O-(CHR'')q-或-(CH2)2-；Y为键或-CH2-；R'为氢或较低的烷基，R''为氢，较低的烷基，CF3，较低的烷氧基，q为0、1、2或3；或其药学上适宜的酸盐。现已发现，该式I的化合物对痕量胺相关受体（TAARs）具有良好的亲和力，特别是对于TAAR1。这些化合物可用于治疗抑郁症，焦虑症，躁郁症，注意力缺陷多动障碍（ADHD），与压力有关的疾病，如精神分裂症，帕金森病等神经疾病，阿尔茨海默病等神经退行性疾病，癫痫，偏头痛，高血压，物质滥用和代谢性疾病，如进食障碍，糖尿病，糖尿病并发症，肥胖症，血脂异常，能量消耗和吸收异常，体温稳态异常，睡眠和昼夜节律异常，以及心血管疾病。
• Pentafluorophenyl Esters: Highly Chemoselective Ketyl Precursors for the Synthesis of α,α-Dideuterio Alcohols Using SmI₂ and D₂O as a Deuterium Source
  作者：Hengzhao Li、Yuxia Hou、Chengwei Liu、Zemin Lai、Lei Ning、Roman Szostak、Michal Szostak、Jie An

  DOI：10.1021/acs.orglett.9b04383

  日期：2020.2.21

  We report the first highly chemoselective synthesis of α,α-dideuterio alcohols with exquisite incorporation of deuterium (>98% [D2]) using pentafluorophenyl esters as ketyl radical precursors, SmI2 as a mild reducing agent, and D2O as the deuterium source. This system tolerates a variety of functional groups, offering rapid entry to valuable α,α-dideuterated alcohol building blocks. More generally

  我们报道了使用五氟苯基酯作为酮基自由基前体，SmI2作为温和的还原剂以及D2O作为氘源的氘（≥98％[D2]）的精细掺入，首次高度化学选择性地合成α，α-二氘代乙醇。该系统可耐受多种功能基团，可快速进入有价值的α，α-二氘代醇构建基块。更一般地，该报告介绍了五氟苯基酯，这是迄今为止报道的最具反应性的O-酮基前体。
• Palladium-Catalyzed Reduction of Acid Chlorides to Aldehydes with Hydrosilanes
  作者：Yasushi Tsuji、Tetsuaki Fujihara、Cong Cong、Tomohiro Iwai、Jun Terao

  DOI：10.1055/s-0032-1317155

  日期：——

  efficient synthesis of aldehydes from acid chlorides with hydrosilanes as a reducing agent in the presence of a palladium catalyst has been achieved. A simple mixture of commercially available Pd(dba)2 and Mes3P as a catalyst realized the reduction of various acid chlorides including aliphatic acid chlorides and α,β-­unsaturated acid chlorides to the corresponding aldehydes in good to high yields under

  在钯催化剂的存在下，用氢硅烷作为还原剂从酰氯有效合成醛。市售的 Pd(dba)2 和 Mes3P 的简单混合物作为催化剂，在温和的反应条件下实现了将包括脂肪族酰氯和 α,β-不饱和酰氯在内的各种酰氯还原为相应的醛类。
• Ligand-controlled divergent dehydrogenative reactions of carboxylic acids via C–H activation
  作者：Zhen Wang、Liang Hu、Nikita Chekshin、Zhe Zhuang、Shaoqun Qian、Jennifer X. Qiao、Jin-Quan Yu

  DOI：10.1126/science.abl3939

  日期：2021.12.3

  inaccessible with existing carbonyl desaturation protocols. Product inhibition is overcome through ligand-promoted preferential activation of C(sp3)–H bonds over C(sp2)–H bonds or a tandem dehydrogenation or vinyl C–H alkynylation sequence. The dehydrogenation reaction is compatible with molecular oxygen as the terminal oxidant.

  通过亚甲基 C-H 活化将烷基链脱氢转化为烯烃仍然是一个重大挑战。我们报道了两类吡啶-吡啶酮配体，它们通过钯催化的β-亚甲基C-H活化羧酸实现不同的脱氢反应，从而直接合成α,β-不饱和羧酸或γ-亚烷基丁烯内酯。这对反应的定向性质允许在其他烯醇化官能团（例如酮）存在下对羧酸进行化学选择性脱氢，从而提供现有羰基去饱和方案无法实现的化学选择性。通过配体促进的 C(sp 3 )–H 键相对于 C(sp 2 )–H 键的优先激活或串联脱氢或乙烯基 C–H 炔基化序列来克服产物抑制。脱氢反应与分子氧作为末端氧化剂相容。

表征谱图